Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net income (loss)	$ 54,554	$ (26,525)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	6,620	6,907
Acquired in-process research & development	0	115,490
Bad debt expense (recoveries)	11	(59)
Stock-based compensation	13,362	12,608
Write-down of inventory and other	2,570	3,508
Accretion on marketable securities	587	918
Change in fair value of other investments	(278)	(17,648)
Gain on previously held interest in preCARDIA	0	(20,980)
Deferred tax provision	(6,373)	6,299
Change in fair value of contingent consideration	(3,359)	871
Other non-cash operating activities	1,080	751
Changes in assets and liabilities:
Accounts receivable	(1,881)	8,763
Inventories	(6,510)	(5,770)
Prepaid expenses and other assets	3,117	(8,697)
Accounts payable	1,438	(4,762)
Accrued expenses and other liabilities	5,583	(16,037)
Deferred revenue	(2,418)	(278)
Net cash provided by operating activities	68,103	55,359
Investing activities:
Purchases of marketable securities	(121,897)	(139,021)
Proceeds from the sale and maturity of marketable securities and other	141,385	123,823
Purchases of other investments	(4,591)	(3,866)
Purchases of property and equipment	(6,783)	(7,170)
Net cash provided by (used for) investing activities	8,114	(109,055)
Financing activities:
Proceeds from the exercise of stock options	1,531	2,120
Taxes paid related to net share settlement upon vesting of stock awards	(10,950)	(9,590)
Repurchase of common stock	(14,517)	0
Net cash used for financing activities	(23,936)	(7,470)
Effect of exchange rate changes on cash and cash equivalents	(4,607)	3,910
Net increase (decrease) in cash and cash equivalents	47,674	(57,256)
Cash and cash equivalents at beginning of period	132,818	232,710
Cash and cash equivalents at end of period	180,492	175,454
Supplemental disclosure of cash flow information:
Cash paid for income taxes, net of refunds	3,542	14,998
Supplemental disclosure of non-cash activities:
Property and equipment in accounts payable and accrued expenses	564	1,014
Right-of-use assets obtained in exchange for lease liabilities	188	283
Precardia
Investing activities:
Payments for acquisition	$ 0	$ (82,821)